Molecular Cancer Therapeutics

Scope
Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the Journal’s main focus is on small molecule and protein drugs, other molecular entities may be considered.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts
Online manuscript submission is welcomed at http://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at http://mct.aacrjournals.org.

Publication Charges
Beginning with manuscripts submitted January 1, 2016 or after, articles will be published with the understanding that the author(s) will pay both a publication fee plus a color figure handling fee. Please see the Instructions for Authors, which are available from the Journal’s home page at http://mct.aacrjournals.org.

Subscription Information
Nonmember Individuals
Subscriptions include print version with online access. Contacts listed below are for nonmember individual subscriptions.

USA and Rest of World (excluding Japan)
American Association for Cancer Research, 615 Chestnut Street, Philadelphia, PA 19106; 1-855-744-4667; pubsales@aacr.org

Japan
e-support@manusen.co.jp; journal@kinokuniya.co.jp; usaco@usaco.co.jp

International print subscriptions include cost of surface mail. Expedited mailing is available. Contact the American Association for Cancer Research for rates.

Advertising Information
For information about advertising in AACR journals, contact Pharmaceutical Media Inc., 30 East 33rd St., 4th Floor, New York, NY 10016; 212-904-0360; Dsimone@pminy.com

Copyright and Permissions
Content printed in or disseminated by Molecular Cancer Therapeutics is protected by copyright. Authors who wish to publish material in Molecular Cancer Therapeutics must formally transfer copyright to the AACR. All authors must sign copyright transfer forms before the AACR can proceed with publication.

AACR Officers
Elizabeth M. Jaffee, President
Elaine R. Mardis, President-Elect
Michael A. Caligiuri, Past President
William N. Hait, Treasurer
Margaret Foti, Chief Executive Officer

Publications Committee
Victor E. Velculescu, Chairperson
Dafna Bar-Sagi
Mary Helen Barcellos-Hoff
Michael E. Berens
John D. Carpten
Maura L. Gillison
Pasi A. Jänne
Gerrit A. Meijer
Gordon B. Mills
Steffi Oesterreich
William Pao
Gloria M. Peterson
David B. Pritchard-Worms
Charles W.M. Roberts
Alice T. Shaw
Lillian L. Siu
Saraswati V. Sukumar
Toshikazu Ushijima

Publishing Staff
Publisher
Christine B. Rullo
Director, Journal Operations and Systems
Daniel S. Evanko
Director, Journal Sales and Marketing
Nicola L. Hill
Director, Electronic Publishing
Robert Spanier
Associate Director, Production
Charlene Squibb
Assistant Director, Journal Marketing
Joanna Arnold
Assistant Director, Institutional Sales & Outreach
Karola Rac
Marketing and Creative Services
Senior Director
Paul Driscoll
Design Staff
Susan Moore